A new (and better?) prostate cancer-specific imaging agent

With the failure of Combidex (ferumoxtran-10) to achieve FDA approval as an imaging agent for  lymph node-positive prostate cancer and the recognized limitations of the ProstaScint (capromab pendetide) scan, there is a widely acknowledged need for a much more specific and accurate prostate cancer imaging agent than anything currently available. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,075 other followers